Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-Related Frailty, is reporting on data from a long-term study. According to the announcement, extended long-term, follow-up data from Longeveron’s ELPIS I trial of Lomecel-B(TM) for patients with hypoplastic left heart syndrome (“HLHS”) is being presented as a poster at the annual Scientific Sessions of the American Heart Association (AHA); those sessions are being held this week, Nov. 11-13, 2023, in Philadelphia. The poster for the sessions is titled “Long-Term Transplant-Free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-Based Therapy.” The poster shows that study data reported 100% of the 10 patients participating in the ELPIS I trial survived and remained heart transplant-free for up to five years of age after receiving Lomecel-B during their stage 2 surgery. Extended follow-up data on all patients enrolled in the study now reflects monitoring for up to five years following treatment with Lomecel-B, with additional follow-up ongoing.
By comparison, historical results from other studies report that children with HLHS experience approximately 20% mortality by five years of age. “Long-term follow-up data from our ELPIS I trial demonstrate the continued survival of the participants, and reinforce potential survival benefit of Lomecel-B for patients with HLHS,” said Longeveron cofounder, chief science officer, and board chair Joshua M. Hare, MD, in the press release. “These data represent an additional up to two years of follow-up data, which point to the potential of Lomecel-B in this indication and provide support for our ongoing ELPIS 2 study, which has exceeded its 50% enrollment threshold. We anticipate completing enrollment in this trial in 2024. There is an unmet need to improve the transplant-free survival for patients with HLHS, and we hope Lomecel-B can significantly improve the treatment landscape for this patient population.”
To view the full press release, visit https://ibn.fm/Mzwxk
About Longeveron Inc.
Longeveron is a clinical-stage, biotechnology company developing regenerative medicines to address unmet medical needs. The company’s lead investigational product is Lomecel-B(TM), an allogeneic medicinal signaling cell (“MSC”) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing provascular, proregenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty. To learn more about the company, visit www.Longeveron.com.
NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at https://ibn.fm/LGVN
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN